Cell therapy, such as regenerative therapies based on iPSCs and adoptive cell therapies targeting cancer with CAR-T cells, CAR-NKs or TCRs hold enormous potential for the future of medicine, enabling for the first time curative approaches. However, the field is still in its infancy and CMC remains a critical bottleneck in bringing these therapies to patients on a global scale.
This discussion will focus on the scientific, technical and cultural transformations required to drive towards true industrialization of cell therapies, including:
- The critical challenges in CMC for cell therapies today
- How more in-depth understanding of cells, their critical quality attributes and control thereof will help drive safety, efficacy and more efficient manufacturing paradigms
- Approaches to manufacture autologous, allogeneic and “next generation” autologous therapies
- Our roadmap to creating an innovative flexible and modular platform to enable true industrialization of CT in the near future
- Partnering models that combine innovation engines with global supply networks to “make it real”
—
SVP & Global Head of Biotech
Bayer Pharmaceuticals
Dr. Jens Vogel is SVP & Global Head of Biotech, Bayer Pharmaceuticals Product Supply, leading biologics operations, development and strategy across five sites, including cell & gene therapy industrialization. Jens has more than 20 years of professional and leadership experience in biologics development, operations, program management and regulatory affairs. Before rejoining Bayer in March 2020, he was President and CEO of Boehringer Ingelheim Fremont and member of BI’s Biopharma Executive Committee. Prior to his years at BI, Jens held various roles of increasing responsibility in Biologics Development at Bayer in Berkeley. He holds a PhD in Biochemical Engineering.
About the Company
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group reported operations in 83 countries, employed about 100,000 people and had sales of 41.4 billion euros. For more information: www.bayer.com.
The Pharmaceuticals division focuses on researching, developing and marketing specialty-focused innovative medicines that provide significant clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. The company is pursuing completely new therapeutic approaches to diseases, strengthening its position in the highly promising area of cell and gene therapy discovery, development and manufacturing.
